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Objective: The 1-34 amino acid segment of the parathyroid hormone (PTH [1-34]) mediates anabolic
effects in chondrocytes and osteocytes. The aim of this study was to investigate whether systemic
application of PTH [1-34] improves the repair of non-osteoarthritic, focal osteochondral defects in vivo.
Design: Standardized cylindrical osteochondral defects were bilaterally created in the femoral trochlea of
rabbits (n ¼ 8). Daily subcutaneous injections of 10 mg PTH [1-34]/kg were given to the treatment group
(n ¼ 4) for 6 weeks, controls (n ¼ 4) received saline. Articular cartilage repair was evaluated by mac-
roscopic, biochemical, histological and immunohistochemical analyses. Reconstitution of the sub-
chondral bone was assessed by micro-computed tomography. Effects of PTH [1-34] on synovial
membrane, apoptosis, and expression of the PTH receptor (PTH1R) were determined.
Results: Systemic PTH [1-34] increased PTH1R expression on both, chondrocytes and osteocytes within
the repair tissue. PTH [1-34] ameliorated the macro- and microscopic aspect of the cartilaginous repair
tissue. It also enhanced the thickness of the subchondral bone plate and the microarchitecture of the
subarticular spongiosa within the defects. No signiﬁcant correlations were established between these
coexistent processes. Apoptotic levels, synovial membrane, biochemical composition of the repair tissue,
and type-I/II collagen immunoreactivity remained unaffected.
Conclusions: PTH [1-34] emerges as a promising agent in the treatment of focal osteochondral defects as
its systemic administration simultaneously stimulates articular cartilage and subchondral bone repair.
Importantly, both time-dependent mechanisms of repair did not correlate signiﬁcantly at this early time
point and need to be followed over prolonged observation periods.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteochondral defects critically affect the articular cartilage and
the underlying subchondral bone1. Due to their intimate cross-
talk2,3, both components of the osteochondral unit need to be
addressed therapeutically4. Established reconstructive surgical
therapies include osteochondral transplantation5 or subchondral
bone grafts combined with autologous chondrocyte implanta-
tion6,7. However, problems such as donor-site morbidity8 and: H. Madry, Center of Exper-
ger Strasse, Building 37-38,
590; Fax: 49-6841-1624569.
mmcucchiarini@hotmail.com
vard.edu (D. Zurakowski),
ohn@uks.eu (D.M. Kohn),
s Research Society International. Pdisturbed remodeling of the osteochondral unit6,9 are unsolved
issues. Moreover, there are currently no systemic or local non-
surgical options available for addressing the problem of limited
osteochondral repair in non-osteoarthritic cartilage defects.
Parathyroid hormone (PTH) is anabolic for osteocytes10 and
chondrocytes11 and its actions are mediated by the PTH receptor
(PTH1R)12. The 1-34 amino acid segment of PTH (PTH [1-34])13 is
approved for the systemic treatment of postmenopausal osteopo-
rosis14. Recent experimental data suggest that PTH [1-34] also en-
hances fracture repair15 and spinal fusion16 in vivo. It further
inhibits the progression of osteoarthritis in mice17 and rats18, and
intraarticular application of the full-length PTH [1-84] molecule via
osmotic pumps over several weeks advanced the repair of shallow
chondral defects in vivo19.
It remains unknown, however, whether PTH [1-34] is capable of
simultaneously stimulating the restoration of the subchondral boneublished by Elsevier Ltd. All rights reserved.
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tested the hypothesis that prolonged subcutaneous application of
PTH [1-34] improves the reconstitution of the entire osteochondral
unit in a translational rabbit osteochondral defect model. We fur-
ther hypothesized that the degree of subchondral bone recon-
stitution correlates with articular cartilage repair in vivo.
Materials and methods
Animal experiments
All animal procedures were approved by the local Governmental
Animal Care Committee. Female Chinchilla bastard rabbits in their
late juvenile stage (n ¼ 8; Charles River, Sulzfeld, Germany; mean
body weight (BW): 3.1 kg (3.0, 3.2); mean age: 14 weeks (12, 16))
were anesthetized by intramuscular injection of Rompun (0.2 ml/
kg BW; Bayer, Leverkusen, Germany) and Ketavet (0.75 mg/kg BW;
Pharmacia & Upjohn, Erlangen, Germany). The knee joint was
entered as previously described1. Two standardized cylindrical
osteochondral defects (diameter 3.2 mm, depth 5.0 mm) were
created in the patellar groove of each knee (n ¼ 32 defects) with
a manual cannulated burr with a ﬂat tip (Synthes, Umkirch, Ger-
many) and a custom made drill stop as previously described1. The
defects were washed with PBS (phosphate buffered saline), the
patella was reduced and the incisions were closed in layers.
Postoperatively, the eight animals were randomly divided into
two groups: the treatment group (PTH group; n ¼ 4) received once
daily (18:00 h) subcutaneous injections of 10 mg/kg BW of human
PTH [1-34] (Bachem, Bubendorf, Switzerland; 74% homology with
lapine PTH [1-34]) dissolved in 0.5 M saline with 2% heat inacti-
vated bovine serum (BS) over 42 days (Table I). Control animals
(n ¼ 4) were daily injected with 0.5 M saline with 2% heat inacti-
vated BS only. The animals were allowed immediate full weight
bearing and were fed a standard diet. No postoperative analgesia
was administered. Two joints were excluded from further analyses
because of macroscopic signs of infection. Blood samples were
collected at days 0, 21, and 42 from all animals and analyzed for
serum levels of calcium and alkaline phosphatase (AP).
After 6 weeks, the rabbits were euthanized with pentobarbital
(150 mg/kg BW; Merial, Hallbergmoos, Germany) and the defects
were photo documented for macroscopic assessment under stan-
dardized illumination conditions20. The entire cartilaginous repair
tissue of the proximal defects was retrieved (n ¼ 14) and stored at
80C for biochemical analysis. The remaining distal femurs
(n ¼ 14) were dissected and ﬁxed in 4% phosphate buffered
formalin.
Macroscopic assessment of the joints
Based on the photographs taken immediately after sacriﬁce, the
defect areas (n ¼ 14) were examined macroscopically in a blinded
fashion. An inverse scoring system20 was applied, incorporatingTable I
Study design. Two standardized osteochondral defects (proximal and distal) were estab
treatment group (n ¼ 4 animals) received daily subcutaneous injections of 10 mg PTH [1-3
each group, one joint had to be excluded from further analysis due to infection. After 6
reconstitution of the subchondral bone was assessed by micro-computed tomography. A
immunohistochemical analyses of the distal defects as well as by biochemical assessment
PTH [1-34] on synovial membrane, apoptosis, and PTH1R expression on osteocytes and
Group Number of
animals
Number of
joints analyzed
Number o
joints infe
PTH [1-34] 4 7 1
Control (saline) 4 7 1individual parameters for color and surface of the repair tissue,
presence of blood vessels, ﬁlling of the defect and integrity of the
adjacent articular cartilage. The individual scores (0e4 points for
each parameter) were combined, resulting in an average total
score ranging from 20 points (no signs of repair) to 0 points
(normal articular cartilage)20.
Micro-computed tomography analysis of the subchondral bone
All trochleas (n¼ 7 per group) were scanned within 70% ethanol
at a spatial resolution of 13 mm in a microfocused X-ray CT scanner
(mCT; Skyscan 1172, Skyscan, Kontich, Belgium) with the tube
voltage set at 70 kV and the current at 140 mA. Projections (1,100e
1,300 per specimen) were obtained at 0.4 intervals with 2,400-ms
exposure time and a combined 0.5 mm aluminium/copper ﬁlter
interposed. Frontal sections were reconstructed by a modiﬁed
Feldkamp cone-beam algorithm21 (NRecon, Skyscan). Thresholding
levels of gray values (range 89e255) were set for segmentation of
binary images. To express gray values as mineral content (bone
mineral density; BMD), calcium hydroxyapatite (CaHA) phantom
rods with known BMD values (250 and 750 mg CaHA/cm3) were
employed for calibration.
Based on the estimated original size of the cylindrical defects
(3.2  5.0 mm), standardized dimensions of 3.0 mm in width
(frontal plane) and length (sagittal plane) were set for all six vol-
umes of interest (VOIs; Fig. 1). Within the defects, the VOI “defect
subchondral bone plate” (defect SBP) involved exclusively the SBP,
“defect subarticular spongiosa” (defect SAS) was located within
trabecular bone. The total depth of both VOIs did not exceed
4.0 mm. The VOIs “lateral adjacent SBP” (lateral SBP) and “medial
adjacent SBP” (medial SBP) were placed within the neighboring
SBPs. Beneath lateral and medial SBP, lateral and medial SAS
adjoined. Overlapping of individual VOIs was avoided (Fig. 1). For
data presentation, the VOIs medial and lateral SBP as wells as
medial and lateral SAS were combined, resulting in the virtual VOIs
adjacent SBP and adjacent SAS, respectively. In one untreated ani-
mal (n ¼ 2 femurs), parameters of normal SBP and SAS were
determined.
BMD, bone volume fraction (BV/TV), bone surface/volume ratio
(BS/BV), and bone surface density (BS/TV) were computed in
a direct 3-dimensional fashion in all VOIs (CT Analyzer, Skyscan).
Cortical thickness (Ct.Th) was evaluated only within the SBP, while
trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), tra-
becular pattern factor (Tb.Pf), trabecular number (Tb.N), structure
model index (SMI), degree of anisotropy (DA), and fractal dimen-
sion (FD) were assessed in the SAS21.
Biochemical evaluation of the repair tissue
Repair tissue retrieved from the proximal defects was thawed
and digested overnight in 100 ml 0.0125% papain solution at 60C.
Digested samples were processed (GENios; Tecan, Crailsheim,lished bilaterally in each trochlea of rabbits (n ¼ 8 animals; n ¼ 32 defects). The
4] per kg BW for 6 weeks16. The control group received daily injections of saline. In
weeks, both components of the osteochondral unit were simultaneously analyzed:
rticular cartilage repair was evaluated by macroscopic, biochemical, histological and
of the repair tissues derived from the proximal defects within each joint. The effect of
chondrocytes was determined
f
cted
Number of
defects analyzed
Subcutaneous
application
Treatment
period
14 Daily 6 Weeks
14 Daily 6 Weeks
Fig. 1. Evaluation of subchondral bone changes by micro-computed tomography.
Overview of a frontal mCT section of the distal femur at the level of the trochlear groove
from a non-operated rabbit (A) and 6 weeks after the creation of an osteochondral
defect (B). The mCT analysis was performed applying the VOIs displayed in image (C),
which represents a magniﬁed view of the area indicated in image (B). SBP-D/SAS-D:
osteochondral defect areas, SBP-M/SAS-M: medial to the defects, SBP-L/SAS-L: lateral
to the defects. The subchondral bone within osteochondral defects (SBP-D, SAS-D) was
signiﬁcantly deteriorated compared to the unaffected, adjacent bone (SBP-M/L, SAS-M/
L). PTH [1-34] application signiﬁcantly increased thickness of the defect SBP (SBP-D),
BV/TV and BMD of the adjacent SBP (SBP-M/L), and microarchitectural parameters of
defect and adjacent SAS (SAS-D, SAS-M/L; Table IV). Scale bars: 5.0 mm (A, B).
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contents by binding to dimethylmethylene blue (DMMB) dye
(Serva, Heidelberg, Germany) and by Hoechst 33258 assay (Sigma,
Munich, Germany), respectively22. Data were normalized to total
cellular proteins using a protein assay (Pierce Thermo Scientiﬁc,
Schwerte, Germany).
Histological and immunohistochemical analyses
Distal femurs were trimmed, decalciﬁed, and parafﬁn-
embedded frontal sections (5 mm) of the distal defects were
stained with safranin orange/fast green (safranin O) or haematox-
ylin/eosin (HE) according to routine protocols23. All histological
scoring was performed blinded. Photomicrographs (Figs. 2e4) were
obtained using a solid-state CCD camera mounted on a BX-45 mi-
croscope (Olympus, Hamburg, Germany).
The synovial membrane was evaluated on HE-stained sections
(n ¼ 14) using a previously published scoring system24. The three
categories in this system include villus thickening (ﬁbrosis), villus
architecture (blunting) and the presence of inﬂammatory cell in-
ﬁltrates. Total point values range between 0 and 9 points.
Visualization of the collagen network (birefringence, ori-
entation, and anisotropy) within the repair tissue was performed
using polarized light microscopy.
Immunostaining was performed as previously described25 using
a 1/50 dilution of a monoclonal mouse anti-type-I or anti-type-II
collagen IgG (both Acris, Hiddenhausen, Germany), a cleaved
caspase-3 polyclonal antibody (Asp175; Cell Signaling Technology,
Frankfurt, Germany), or a monoclonal mouse PTH1R antibody
(ab3271; Abcam, Cambridge, UK), and a secondary biotinylated
anti-mouse antibody (Vector Laboratories, Grünberg, Germany).
Immunoreactivity to type-I collagen in the repair tissue was com-
pared with that of the adjacent subchondral bone, serving as
a positive internal control. Immunoreactivity to type-II collagen in
the repair tissue was compared with that of the adjacent articular
cartilage. A scorewas given to each kneewith 0 points indicating no
immunoreactivity; 1: signiﬁcantly weaker; 2: moderately weaker;
3: similar, and 4: stronger immunoreactivity compared with the
internal controls. Immunoreactivity to both collagens was alsocompared with normal lapine articular cartilage. For the evaluation
of caspase-3 immunostaining, images of the histological sections
taken at 200-fold magniﬁcation were digitalized and six stan-
dardized regions of interest (ROIs; 0.1 mm2) were deﬁned within
and adjacent to the defects in the superﬁcial cartilage layer (apical
half), the deep cartilage layer (basal half) and the subchondral bone
(analySIS docu 5.0, Olympus Soft Imaging Solutions, Münster,
Germany). Total cell numbers and apoptosis rates were determined
histomorphometrically (Table II). PTH1R expression was deter-
mined as the percentage of stained cells in six standardized ROIs
(0.1 mm2 each) within repair cartilage and repair subchondral
bone. Two sections were scored per defect and antibody.
Degenerative changes in the articular cartilage adjacent to the
defects were evaluated within a 3 mm area neighboring both
integration sides (excluding the area of integration) on safranin O-
stained sections, applying the scoring system for osteoarthritic
lapine cartilage of Laverty et al.26 (Table III).
For quantitative assessment of the repair tissue, serial histo-
logical sections of the distal femora were taken at 200 mm intervals.
Safranin O-stained sections within approximately 1.0 mm from the
center of the defect (n ¼ 8e10 per defect) were analyzed using the
simple articular cartilage repair scoring system according to
Wakitani et al.27 and the complex score described by Sellers
et al.28,29 (Table III). A total of 116 sections were scored twice by one
blinded investigator.
Correlation between articular cartilage and subchondral bone repair
Correlations between the histological total average point values
and the key mCT parameters BMD, BV/TV and Ct.Th or Tb.Th from
VOIs comprising deteriorated cortical (defect SBP) and trabecular
(defect SAS) subchondral bone were determined.
Statistical analysis
Each test condition was performed with n ¼ 4 independent
animals (n ¼ 7 joints) per group. Since the data involve multiple
observations on different joints from the same animals, these are
likely positively correlated when compared to observations from
a different animal. In order to obtain mean comparisons in the
context of a model that takes into account these correlations, we
employed a linear model using generalized estimating equations
(GEE) with an exchangeable working correlation structure (which
with no more than two observations per animal, is an entirely
general structure). Standard errors were based on a robust esti-
mated covariance matrix (Huber-White or “sandwich” estimator).
The BlandeAltman method for calculating weighted correlation
coefﬁcients (r) between subjects with repeated observations30 was
used to determine the strength of association between the histo-
logical average total scores27,28 and key mCT parameters. Based on
sample sizes and differences in mCT parameters of subchondral
bone, a power of 80% for detecting large treatment effects
(approximately 1.3e1.5 standard deviations) was achieved. Data are
presented as mean values, 95% conﬁdence intervals are used to
denote statistical uncertainty of estimates and are given in
parentheses. Two-tailed values of P < 0.05 were considered sig-
niﬁcant. Statistical analyses were performed using the SPSS soft-
ware package (version 19.0, SPSS Inc./IBM, Chicago, IL).
Results
Effect of systemic PTH [1-34] application on PTH1R expression
PTH [1-34] induced a consecutive up-regulation of PTH1R
expression on both, osteocytes within the repaired subchondral
Fig. 2. PTH1R expression in osteochondral defects and exclusion of potential deleterious responses following systemic PTH [1-34] administration in vivo. Prolonged PTH [1-34]
treatment induced an up-regulation of PTH1R expression on both, osteocytes within the subchondral bone (A) and chondrocytes of the articular cartilage (B) from osteochon-
dral defect areas. This simultaneous response of both cell populations constituting the osteochondral unit might explain the coexistent improvement of articular cartilage and
subchondral bone repair in osteochondral defects by PTH [1-34]. The treatment neither induced an increase in the apoptosis rate of osteocytes (C) and chondrocytes (D) within the
repair tissue nor an inﬂammatory response in the synovial membrane (E). Arrowheads (AeD) point at some of the immunopositive cells. Sections were taken from defects having
a histological rating equal to the mean score for its respective treatment group. Negative controls (left images in AeD) show immunostainings with omission of the primary
antibody. Triangles in (E) delimit the thickness of the apical layer of the synovial membrane which overlies a stroma of loose soft tissue rich in collagen ﬁbers and adipocytes. Graphs
indicate mean values and 95% conﬁdence intervals (error bars) based on n ¼ 4 independent observations. Scale bars: 0.2 mm.
P. Orth et al. / Osteoarthritis and Cartilage 21 (2013) 614e624 617bone (64% (59, 69) vs 38% (32, 43) positive cells (P < 0.001)) and
chondrocytes within the cartilage repair tissue (57% (51, 62) vs 9%
(3, 15); P < 0.001; Fig. 2) when compared to controls.
Effect of PTH [1-34] on calcium and AP levels
Before PTH [1-34] administration, no differences were detected
between PTH and control groups in calcium (3.53 mmol/l (3.35,
3.70) vs 3.69 mmol/l (3.29, 4.09); P ¼ 0.51) and AP serum levels
(80.50 U/l (74.70, 86.30) vs 76.50 U/l (62.22, 90.78); P ¼ 0.64). At
day 21, similar results were obtained (calcium: 3.61 mmol/l (3.58,
3.64) vs 3.48 mmol/l (3.31, 3.65): P ¼ 0.40; AP: 81.00 U/l (69.91,
92.09) vs 75.00 U/l (45.90,104.10): P¼ 0.81). However, serum levels
for calcium (4.10 mmol/l (3.87, 4.32) vs 3.58 mmol/l (3.41, 3.75);P¼ 0.01) and AP (90.25 U/l (85.99, 94.51) vs 69.25 U/l (62.12, 76.38);
P ¼ 0.004) were signiﬁcantly increased after 42 days of PTH [1-34]
administration compared with controls.
Examination of potential deleterious responses to PTH [1-34]
Apoptosis rate of chondrocytes and osteocytes
Cell numbers and apoptosis rates of chondrocytes and osteo-
cytes in different compartments of the osteochondral unit are given
in Table II. Caspase-3 immunoreactivity was signiﬁcantly higher in
the superﬁcial than in the deep zone of the cartilage repair tissue
(P ¼ 0.04). Systemic application of PTH [1-34] had no signiﬁcant
effect on the rate of apoptosis in any of the regions evaluated (all
P > 0.10; Fig. 2).
Fig. 3. Macroscopic and histological assessment of articular cartilage repair following systemic PTH [1-34] application in vivo. Compared to controls, treatment with PTH [1-34]
signiﬁcantly improved the macroscopic appearance20 of the articular cartilage repair tissue (A). This improvement was also reﬂected in the histological evaluation following
staining with safranin O (B, C) or HE (D), applying either a simple27 (B) or a complex28 (C) scoring system. Sections were taken from defects having a histological rating equal to the
mean score for its respective treatment group. Margins of the defects are denoted by black triangles. Graphs indicate mean values and 95% conﬁdence intervals (error bars) based on
n ¼ 4 independent observations. Scale bars: 5.0 mm (A), 2.0 mm (B), or 1.0 mm (C, D).
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According to the applied scoring system24, there were no dif-
ferences (all P > 0.70) in the thickness (mean score 0.3 (0.1, 0.6) vs
0.4 (0.1, 0.6)) or architecture (0.6 (0.1, 1.1) vs 0.5 (0, 1.0)) of synovial
villi or in the presence of inﬂammatory cell inﬁltrates (0.4 (0, 0.8) vs
0.3 (0, 0.7)) between knees of the PTH group and control joints
(Fig. 2). The average total scores were comparatively low for both
groups (1.3 (0.1, 2.4) vs 1.3 (0.2, 2.5); P¼ 0.95), indicating the lack of
synovial changes induced by systemic PTH [1-34].
Effect of PTH [1-34] on articular cartilage repair
Macroscopic evaluation
After 6 weeks in vivo, systemic PTH [1-34] application yielded
a signiﬁcant transformation of the color of the repair tissue20 from
white to hyaline (1.1 (0.9, 1.4) vs 0.1 (0, 0.4); P < 0.001), and
improved the defect surface (1.0 (1.0, 1.0) vs 1.7 (1.7, 1.7; P < 0.001))
and the average total score (2.1 (1.9, 2.4) vs 4.7 (4.4, 4.9); P < 0.001;
Fig. 3) compared to controls.Biochemical characterization of the cartilaginous repair tissue
Systemic PTH [1-34] application did not affect the ratio of pro-
teoglycan per protein mass (0.06 mg/mg (0.04, 0.09) vs 0.07 mg/mg
(0.04, 0.10); P ¼ 0.69) and DNA per protein mass (16.31 ng/mg (7.21,
25.40) vs 22.20 ng/mg (13.10, 31.29); P ¼ 0.37) within the repair
tissues. The ratio of proteoglycan per DNA remained consistently
low irrespective of whether the tissues were exposed to PTH [1-34]
or not (0.01 mg/ng (0, 0.02) vs 0 mg/ng (0, 0.01); P ¼ 0.26).
Degenerative changes in the adjacent articular cartilage
PTH [1-34] application led to a signiﬁcantly increased formation
of clusters (chondrons; P¼ 0.03) in the adjacent cartilage. However,
the average total score of cartilage degradation26 remained un-
changed between PTH and control group (Table III).
Histological grading of articular cartilage repair
Applying the elementary Wakitani score27 to evaluate cartilage
repair, PTH [1-34] administration signiﬁcantly improved surface
regularity (3.3-fold) and integration of the cartilaginous repair
Fig. 4. Collagen distribution within the osteochondral unit. PTH [1-34] did not provoke changes in the immunoreactivity to a monoclonal mouse anti-human type-I collagen IgG (A)
or to a monoclonal mouse anti-human type-II collagen IgG (B) at this early time point of 6 weeks after defect creation. In both groups, collagen ﬁbrils within the repair tissue did not
reproduce a normal articular cartilage organization, but birefringence of the subchondral bone was similar between defects and the adjacent bone (C). Sections were taken from
defects having a histological rating equal to the mean score for its respective treatment group. Normal controls (left images in AeC) show the intact osteochondral unit of a non-
operated lapine trochlear groove. Margins of the defects are denoted by triangles. Graphs indicate mean values and 95% conﬁdence intervals (error bars) based on n ¼ 4 inde-
pendent observations. Scale bars: 1.0 mm.
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value was signiﬁcantly improved following treatment with PTH [1-
34] (P < 0.001; Fig. 3).
When the complex histological scoring system of Sellers et al.28
was used, the individual parameters of integration (1.3-fold), ma-
trix staining (8.3-fold), and defect as well as surface architecture
(2.2-fold and 1.8-fold, respectively) were signiﬁcantly improved in
the PTH group (all P< 0.05; Table III). Importantly, the average total
score was signiﬁcantly improved by PTH [1-34] (P < 0.001; Fig. 3),
and highly correlated with the Wakitani total score (r ¼ 0.978
(0.878e0.996); P < 0.001).Distribution of collagens within the osteochondral unit
Polarized light microscopy
Polarized light microscopic assessment revealed that collagen
ﬁbrils within the repair tissue of both groups did not reproduce
a normal articular cartilage organization. Irrespective of the treat-
ment, birefringence (an indicator of collagen content) was alwaysTable II
Cell numbers and apoptosis rates in different compartments of the osteochondral unit. C
within and adjacent to the osteochondral defects in the superﬁcial cartilage layer (apical
were higher for chondrocytes in the superﬁcial than in the deep zone of the cartilage re
numbers and on the rate of apoptosis in any of the regions evaluated
Region Total cell number
PTH [1-34] Control
Defect: superﬁcial cartilage 114.8 (95.4, 134.1) 147.5 (114.1, 180.9
Defect: deep cartilage 113.5 (84.7, 142.3) 148.0 (121.0, 175.0
Defect: subchondral bone 79.8 (58.4, 101.1) 102.5 (60.6, 144.4)
Adjacent: superﬁcial cartilage 105.5 (97.5, 113.5) 96.8 (88.3, 105.2)
Adjacent: deep cartilage 81.3 (66.6, 95.9) 95.8 (82.6, 108.9)
Adjacent: subchondral bone 69.0 (50.1, 87.9) 91.8 (74.4, 109.1)weaker within the repair tissues than in the surrounding cartilage
(Fig. 4). Birefringence of the subchondral bone was similar between
the defect areas and the adjacent tissue in both groups.
Type-I and type-II collagen immunostaining
At this early time point, immunoreactivity to type-I collagenwas
similar in the cartilage repair tissue of animals from the PTH group
(mean score 2.4 (1.5, 3.3)) and the control group (2.0 (1.1, 2.9);
P ¼ 0.57). Between both groups, no differences were detected for
the presence of type-II collagen in the cartilage repair tissues,
amajor component of hyaline articular cartilage (2.6 (2.4, 2.9) vs 2.7
(2.5, 3.0); P ¼ 0.64; Fig. 4).Effect of PTH [1-34] on the microarchitecture of the subchondral
bone
Evaluation of adjacent subchondral bone
PTH [1-34] enhanced BV/TV and BMD as well as Ct.Th of the
adjacent SBP (Table IV). Simultaneously, PTH [1-34] enhanced Tb.Thaspase-3 immunoreactivity was evaluated in six standardized ROIs (0.1 mm2 each)
half), the deep cartilage layer (basal half), and the subchondral bone. Apoptosis rates
pair tissue. Systemic application of PTH [1-34] had no signiﬁcant effect on total cell
Apoptosis rate
P PTH [1-34] Control P
) 0.16 29.5 (10.3, 48.7) 28.8 (9.6, 48.0) 0.96
) 0.20 0 (0, 0.4) 0.5 (0.1, 0.9) 0.11
0.40 30.1 (9.3, 50.9) 46.7 (26.0, 67.5) 0.27
0.19 2.1 (0, 14.3) 12.9 (0.7, 25.2) 0.22
0.20 5.7 (0.3, 11.1) 8.8 (3.3, 14.2) 0.44
0.11 22.5 (3.3, 41.6) 23.1 (13.0, 33.1) 0.95
Table III
Applied inverse histological grading systems and obtained score values for the histological evaluation of the adjacent articular cartilage26 and the cartilaginous repair tis-
sues27,28. Effect of PTH [1-34] application on the histological grading of the adjacent articular cartilage (Laverty26 score) and the cartilage repair tissue (Wakitani27 and Sellers28
scores) at 6 weeks in vivo. Mean values and 95% conﬁdence intervals represent the estimated scores in points for each category and the average total scores; lower point values
indicate a better histological appearance of the tissue. PTH [1-34] administration did not affect degenerative changes in the adjacent articular cartilage. The treatment
improved all individual parameters of the repair tissues in both scores and signiﬁcantly improved the total average scores (both P < 0.05), indicating a better quality of the
cartilage repair tissue following PTH [1-34] administration. Statistical signiﬁcance is highlighted by bold letters
Assignable point values PTH [1-34] Control X-fold P
Laverty score26
Matrix staining (0e6) 3.79 (2.42, 5.17) 4.35 (2.98, 5.73) 0.87 0.57
Structure (0e11) 2.84 (1.09, 4.60) 1.78 (0.02, 3.53) 1.60 0.40
Chondrocyte density (0e4) 1.86 (0.61, 3.12) 1.84 (0.58, 3.09) 1.01 0.98
Cluster formation (0e3) 1.96 (1.58, 2.35) 1.35 (0.97, 1.74) 1.45 0.03
Average total score (0e24) 10.18 (6.22, 14.14) 9.22 (5.26, 13.18) 1.10 0.74
Wakitani score27
Cell morphology (0e4) 0.97 (0.80, 1.14) 1.13 (0.97, 1.31) 1.16 0.18
Matrix staining (0e3) 0.13 (0, 0.43) 0.32 (0.02, 0.61) 2.46 0.39
Surface regularity (0e3) 0.62 (0.06, 1.18) 2.06 (1.50, 2.62) 3.32 <0.001
Thickness (0e2) 0 (0, 0) 0 (0, 0) 1.00 n.a.
Integration (0e2) 0.44 (0.27, 0.62) 0.86 (0.68, 1.03) 1.95 0.001
Average total score (0e14) 2.17 (1.36, 2.98) 4.37 (3.56, 5.19) 2.01 <0.001
Sellers score28
Filling of defect (0e4) 0 (0, 0.17) 0.21 (0.04, 0.37) n.a. 0.09
Integration (0e3) 1.44 (1.22, 1.67) 1.90 (1.68, 2.13) 1.32 0.01
Matrix staining (0e4) 0.04 (0, 0.24) 0.33 (0.14, 0.53) 8.25 0.04
Cell morphology (0e5) 1.99 (1.64, 2.33) 2.21 (1.86, 2.55) 1.11 0.38
Architecture (defect) (0e4) 0.64 (0.33, 0.96) 1.41 (1.10, 1.72) 2.20 0.001
Architecture (surface) (0e3) 1.18 (0.71, 1.65) 2.06 (1.59, 2.53) 1.75 0.01
Subchondral bone (0e4) 0.27 (0, 0.79) 0.98 (0.47, 1.50) 3.63 0.06
Tidemark (0e4) 3.04 (2.69, 3.39) 3.80 (3.44, 4.15) 1.25 0.003
Average total score (0e31) 8.64 (7.07, 10.21) 12.92 (11.35, 14.49) 1.50 <0.001
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surface indices (BS/BV, BS/TV) in the adjacent SBP, but increased
them in the adjacent SAS.
Evaluation of osteochondral defects
Within the defects, PTH [1-34] increased thickness (Ct.Th) and
mineral density (BMD) of the repaired SBP (defect SBP; Table IV)
and the Tb.Th of the SAS (defect SAS), while decreasing Tb.Sp. PTH
[1-34] further enhanced the connectivity of the spongious network
(decreased Tb.Pf) and induced a change from a more rod-like to the
native plate-like geometrical pattern (decreased SMI (1.37 vs 0.72);
normal SMI: 0.74).
Evaluation of normal subchondral bone
Values of normal SBP and SAS are given in Table IV. No apparent
differences were detected between adjacent SBP or SAS of operated
control animals and normal SBP or SAS of non-operated animals.
Correlation between articular cartilage and subchondral bone repair
All BlandeAltman weighted correlation coefﬁcients between
the key mCT parameters BMD, BV/TV, and Ct.Th or Tb.Th from
subchondral bone defects (defect SBP and SAS; Table IV) and his-
tological average total scores of the Wakitani27 and Sellers28 scores
(Table III) failed to attain statistical signiﬁcance (all P > 0.12). This
suggests that analysis of repair tissues at only one time point and
with a small number of animals did not demonstrate time-
dependent mechanisms of repair.
Discussion
The major ﬁnding of this study is that PTH [1-34] simulta-
neously improved the macro- and microscopic aspect of articular
cartilage repair and the microarchitecture of the subchondral bone
in focal osteochondral defects after 6 weeks in vivo. Intriguingly,
these coexistent improvements of cartilage and bone repair did notcorrelate signiﬁcantly. Of note, systemic application of PTH [1-34]
directly affected the cells mediating osteochondral repair, as
PTH1R expression was signiﬁcantly up-regulated on the chon-
drocytes and osteocytes within the repair tissue. PTH [1-34]
emerges therefore as a promising agent in the complex process of
osteochondral repair31, in addition to its clinically useful role to play
in osteoarthritis17,18,32 and bone repair33e35. This is of high signiﬁ-
cance, because there are currently no systemic therapies available
to address the limited repair of focal, non-osteoarthritic osteo-
chondral defects.
To date, only a few studies have simultaneously assessed the
inﬂuence of PTH on articular cartilage and subchondral bone repair.
Kudo et al.19 found improved repair of focal chondral defects by
intraarticular PTH [1-84] application via osmotic pumps but no
effect on the subchondral bone as determined by histo-
morphometry. PTH [1-34] (10 mg/kg BW/day; 50 days) reversed
osteoporotic subchondral bone changes and reduced cartilage
degeneration in a rabbit model of both, osteoporosis and osteo-
arthritis, with the regression of cartilage damage being ascribed to
an ameliorated subchondral bone support36. In the present study
with a small sample size and only one time point investigated, the
coexistent increase in bone density (BMD, BV/TV) and improve-
ment of cartilage repair e most likely ascribed to the enhanced
PTH1R expression on chondrocytes and osteocytes37 e did not
correlate signiﬁcantly. However, the relatively short observation
period of 6 weeks may have inﬂuenced the ﬁndings on cartilage
and bone repair, as maturation of both tissues is time-dependent.
Thus, extended time points are required and further investigations
will be needed to elucidate whether the enhanced bone density is
beneﬁcial for long-term cartilage repair or rather reﬂects sclerosis,
a feature of osteoarthritis.
PTH [1-34] increases BMD14, Ct.Th33 and Tb.Th38, Tb.N and
connectivity34, enhancing bone strength and reducing the risk of
fracture in animal models35 and patients14. In a mCT evaluation of
the subchondral bone in osteoporotic rabbits, Bellido et al.36 found
PTH [1-34] to increase the volume and thickness of cortical and
Table IV
Micro-computed tomography parameters determined in different VOIs within and adjacent to osteochondral defects. Compared to controls, PTH [1-34] application signiﬁcantly increased thickness (Ct.Th) of the defect SBPBV/TV
and BMD of the adjacent SBP and themicroarchitecture of defect and adjacent SAS. No differences were detected between adjacent SBP or SAS of operated control animals and normal SBP or SAS of non-operated animals. Data are
presented as mean values and 95% conﬁdence intervals. BMD: bone mineral density, BV/TV: bone volume fraction, BS/BV: bone surface/volume ratio, BS/TV: bone surface density, Ct.Th: cortical thickness, Tb.Th: trabecular
thickness, Tb.Sp: trabecular separation, Tb.Pf: trabecular pattern factor, Tb.N: trabecular number, SMI: structure model index, DA: degree of anisotropy, FD: fractal dimension21, n.a.: not applicable (parameters for trabecular SAS
not suitable for cortical SBP and vice versa). Statistical signiﬁcance is highlighted by bold letters
Parameter Unit SBP SAS
Defect SBP Adjacent SBP Normal SBP Defect SAS Adjacent SAS Normal SAS
PTH [1-34] Control P PTH [1-34] Control P PTH [1-34] Control P PTH [1-34] Control P
BMD mg/
cm3
767.16
(739.05,
795.27)
720.22
(694.08,
746.36)
0.02 840.96
(826.62,
855.30)
741.10
(727.30,
754.90)
<0.001 758.22
(725.64,
790.80)
778.77
(702.67,
854.86)
704.76
(638.86,
770.66)
0.15 757.96
(730.37,
785.55)
749.86
(723.55,
776.17)
0.68 735.18
(690.60,
779.76)
BV/TV % 50.45 (40.52,
60.39)
45.42 (36.45,
54.40)
0.46 86.51 (81.50,
91.52)
66.86 (62.02,
71.70)
<0.001 63.55 (57.54,
69.65)
12.55 (10.10,
15.00)
14.15 (11.83,
16.47)
0.35 22.25 (20.40,
24.10)
20.55 (18.90,
22.21)
0.18 22.70 (19.44,
25.95)
BS/BV mm1 45.43 (36.43,
54.43)
58.19 (50.03,
66.36)
0.04 28.82 (26.06,
31.57)
47.85 (45.40,
50.30)
<0.001 44.33 (36.59,
52.08)
51.45 (47.76,
55.16)
59.08 (55.86,
62.31)
0.01 46.90 (44.16,
49.63)
42.77 (40.22,
45.32)
0.03 38.54 (34.05,
43.02)
BS/TV mm1 22.82 (19.11,
26.52)
25.10 (21.74,
28.45)
0.04 23.73 (23.27,
24.19)
30.34 (29.88,
30.79)
<0.001 27.60 (21.83,
33.38)
6.50 (5.04,
7.95)
8.70 (7.35,
10.05)
0.03 10.50 (9.91,
11.09)
8.53 (8.01,
9.05)
0.001 7.79 (6.45,
9.13)
Ct.Th mm 0.25 (0.22,
0.27)
0.19 (0.17,
0.22)
0.01 0.36 (0.34,
0.38)
0.23 (0.21,
0.25)
<0.001 0.25 (0.22,
0.27)
n.a. n.a. n.a. n.a. n.a.
Tb.Th mm n.a. n.a. n.a. n.a. n.a. 0.08 (0.07,
0.08)
0.06 (0.06,
0.06)
0.01 0.09 (0.08,
0.09)
0.07 (0.07,
0.08)
0.01 0.08 (0.06,
0.10)
Tb.Sp mm n.a. n.a. n.a. n.a. n.a. 0.46 (0.38,
0.55)
0.78 (0.70,
0.85)
0.01 0.33 (0.31,
0.35)
0.38 (0.36,
0.40)
0.001 0.41 (0.34,
0.47)
Tb.Pf mm1 n.a. n.a. n.a. n.a. n.a. 4.90
(9.22,
0.58)
3.87 (0.05,
7.81)
0.01 3.43
(8.11, 1.26)
3.95
(8.21, 0.31)
0.87 4.48
(5.62,
3.34)
Tb.N mm1 n.a. n.a. n.a. n.a. n.a. 1.75 (1.33,
2.16)
2.17 (1.78,
2.55)
0.15 2.85 (2.71,
2.99)
2.31 (2.17,
2.45)
0.001 2.15 (2.05,
2.24)
SMI / n.a. n.a. n.a. n.a. n.a. 0.72 (0.38,
1.06)
1.39 (1.08,
1.71)
0.01 0.46 (0.06,
0.85)
0.54 (0.18,
0.90)
0.75 0.74 (0.28,
1.20)
DA / n.a. n.a. n.a. n.a. n.a. 0.66 (0.61,
0.70)
0.65 (0.61,
0.69)
0.80 0.47 (0.46,
0.49)
0.49 (0.48,
0.51)
0.52 0.55 (0.42,
0.68)
FD / n.a. n.a. n.a. n.a. n.a. 2.34 (2.28,
2.39)
2.30 (2.25,
2.35)
0.30 2.28 (2.25,
2.32)
2.31 (2.28, 2.34) 0.30 2.32 (2.32,
2.32)
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P. Orth et al. / Osteoarthritis and Cartilage 21 (2013) 614e624622trabecular subchondral bone. These results are in good agreement
with the present study in which PTH [1-34] exerted its effects on
both, the SBP and the SAS, yielding a larger area of reconstituted
subchondral bone in the treatment group while control defects
were still repairing at 6 weeks. However, the effects of PTH [1-34]
on the subchondral bone are not necessarily an improvement, but
may also indicate the initiation of osteoarthritis39,40. Remarkably,
this impact on the osseous microarchitecture was accompanied by
an increase in serum levels of calcium and AP.
Apart from the well-documented anabolic effects of PTH [1-34]
on bone, its in vivo impact on articular cartilage is seldom
described. For osteoarthritis, Chang et al.18 and Sampson et al.17
have shown that PTH [1-34] may inhibit the progress of carti-
lage degeneration in rat or mouse knees after 5 or 12 weeks
in vivo, respectively. The negative correlation between PTH1R
expression and the histological grading of lapine osteoarthritic
cartilage32 may explain this ﬁnding. Kudo et al. studied the effect
of intraarticular administration of human PTH [1-84] on full-
thickness chondral defects in the rabbit trochlea. Although the
treatment induced articular cartilage repair e possibly by
enhancing mesenchymal cell proliferation19 e it inhibited chon-
drogenic differentiation of progenitor cells41. Feeley et al.42 even
described a deleterious effect of 10 mg PTH [1-34]/kg BW/day (over
1 or 4 weeks) on the histological characteristics of cartilage repair
three months after microfracture treatment of 6 mm chondral
defects in rabbits. In the present study, the same dose improved
the macroscopic appearance and the overall histological grading
of the cartilage repair tissue in two scoring systems27,28 with
a high inter-score correlation (r ¼ 0.98). However, the immuno-
reactivity of the repair tissues to type-I and type-II collagen
remained unaffected by PTH [1-34], possibly because either
maximum collagen expression was already achieved or differen-
tiation of the repair tissue (type-II collagen deposition vis-à-vis
type-I collagen reduction) had not yet commenced after 6 weeks
in vivo. Besides, the biochemical composition of the repair tissue
remained unchanged. Notably, this supports our previous ﬁnding
that histological and biochemical parameters of articular cartilage
repair do not correlate29. PTH [1-34] induced neither proliferation
of cells repopulating the defects (unchanged DNA concentrations
and total cell numbers; Table II), neither apoptosis of chon-
drocytes and osteocytes, and the reported percentages of apop-
totic chondrocytes and osteocytes are in good agreement with
literature values43,44. Further, the treatment did not yield degen-
erative changes in the adjacent cartilage or an inﬂammatory
response in the synovial membrane. This is of clinical importance,
as synovialitis contributes to cartilage degeneration45.
The signiﬁcantly up-regulated expression of PTH1R on osteo-
cytes within the repaired subchondral bone and chondrocytes
within the cartilaginous repair tissue indicates that systemic
application of PTH [1-34] was capable of directly stimulating these
local cells. Both, articular chondrocytes11 and osteocytes10 express
PTH1R, and binding of PTH [1-34] to its receptor46 may enhance the
expression and production of growths factors with downstream
effect on their antagonists47.
The dosage of PTH [1-34] varies considerably among exper-
imental investigations35. Here, 10 mg PTH [1-34]/kg BW/day16 were
chosen because metaphyseal bone healing of rabbits48 was
improved by the same dose over 4 weeks. While intermittent and
short-term stimulation of PTH [1-34] favors bone formation in
animals49 and patients14, a higher dosage (40 mg/kg BW/day for 20
weeks)50 or persistently high levels induce a signiﬁcant loss in
animal BW and increased serum calcium and AP concentration.
In conclusion, systemic administration of PTH [1-34] simulta-
neously stimulates articular cartilage and subchondral bone repair
in focal osteochondral defects. PTH [1-34] therefore emerges as animportant therapeutic treatment option in the complex process of
osteochondral repair.
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